FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3109850965> ?p ?o ?g. }

• W3109850965 endingPage "49" @default.
• W3109850965 startingPage "39" @default.
• W3109850965 abstract "Netakimab (NTK) is a humanized anti-interleukin-17A monoclonal antibody. To date, the drug has been approved to treat ankylosing spondylitis (AS), psoriatic arthritis, and plaque psoriasis. The paper gives the data obtained during 52-week follow-up of AS patients in the phase III ASTERA study. Objective : to study the efficacy and safety of NTK when used long in patients with active AS. Patients and methods . The investigation enrolled 228 patients with active AS, in whom nonsteroidal anti-inflammatory drugs or biological agents were ineffective. The patients were randomized in a 1:1 ratio to receive NTK 120 mg or placebo. The drug was administered subcutaneously at weeks 0, 1, 2, and then once every 2 weeks. Patients who received placebo and achieved a 20% improvement according to the ASAS criteria (ASAS20) were excluded from the study at week 16. At this week, patients who took placebo and did not achieve an ASAS20 response were switched to subcutaneous NTK at 120 mg dose once every two weeks. The follow-up period was 52 weeks. Results and discussion . Patients with active AS who received NTK were more likely to respond to treatment than those who took placebo. The proportion of people who achieved 40% improvement (ASAS40) during treatment with NTK increased throughout the follow-up period and amounted to 80.7% at week 52. Positive changes were achieved in all used clinical and laboratory parameters of AS activity. There was also a decrease in inflammatory changes, as shown by magnetic resonance imaging (MRI). The adverse events (AEs) were mainly laboratory abnormalities and upper respiratory tract infections. Treatment-related AEs were recorded in no more than one third of patients and they were mild to moderate. Severe AEs were singular. Conclusion . Response to NTK therapy generates in the first weeks of drug use and increases throughout a year. The safety profile of NTK when used long is generally favorable." @default.
• W3109850965 created "2020-12-07" @default.
• W3109850965 creator A5002259667 @default.
• W3109850965 creator A5003107578 @default.
• W3109850965 creator A5003682830 @default.
• W3109850965 creator A5005224936 @default.
• W3109850965 creator A5008384446 @default.
• W3109850965 creator A5012081749 @default.
• W3109850965 creator A5016536735 @default.
• W3109850965 creator A5017143127 @default.
• W3109850965 creator A5018132469 @default.
• W3109850965 creator A5025637560 @default.
• W3109850965 creator A5026435595 @default.
• W3109850965 creator A5034797711 @default.
• W3109850965 creator A5045333833 @default.
• W3109850965 creator A5045484635 @default.
• W3109850965 creator A5047377148 @default.
• W3109850965 creator A5048381438 @default.
• W3109850965 creator A5055501716 @default.
• W3109850965 creator A5064457355 @default.
• W3109850965 creator A5064789713 @default.
• W3109850965 creator A5075361314 @default.
• W3109850965 creator A5080853611 @default.
• W3109850965 creator A5084314819 @default.
• W3109850965 creator A5088414167 @default.
• W3109850965 creator A5089682169 @default.
• W3109850965 creator A5090816037 @default.
• W3109850965 date "2020-11-25" @default.
• W3109850965 modified "2023-10-14" @default.
• W3109850965 title "Long-term efficacy and safety of netakimab in the treatment of ankylosing spondylitis: results of Phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA" @default.
• W3109850965 cites W1631490048 @default.
• W3109850965 cites W2034699258 @default.
• W3109850965 cites W2058882501 @default.
• W3109850965 cites W2113750014 @default.
• W3109850965 cites W2133816416 @default.
• W3109850965 cites W2278932593 @default.
• W3109850965 cites W2564945411 @default.
• W3109850965 cites W2591276563 @default.
• W3109850965 cites W2769953079 @default.
• W3109850965 cites W2770642598 @default.
• W3109850965 cites W2892870028 @default.
• W3109850965 cites W2895180416 @default.
• W3109850965 cites W2896552337 @default.
• W3109850965 cites W2897890026 @default.
• W3109850965 cites W2959572524 @default.
• W3109850965 cites W2981429009 @default.
• W3109850965 cites W2982785161 @default.
• W3109850965 cites W3044956838 @default.
• W3109850965 cites W3083737813 @default.
• W3109850965 cites W4255613904 @default.
• W3109850965 doi "https://doi.org/10.14412/1996-7012-2020-4-39-49" @default.
• W3109850965 hasPublicationYear "2020" @default.
• W3109850965 type Work @default.
• W3109850965 sameAs 3109850965 @default.
• W3109850965 citedByCount "6" @default.
• W3109850965 countsByYear W31098509652021 @default.
• W3109850965 countsByYear W31098509652022 @default.
• W3109850965 countsByYear W31098509652023 @default.
• W3109850965 crossrefType "journal-article" @default.
• W3109850965 hasAuthorship W3109850965A5002259667 @default.
• W3109850965 hasAuthorship W3109850965A5003107578 @default.
• W3109850965 hasAuthorship W3109850965A5003682830 @default.
• W3109850965 hasAuthorship W3109850965A5005224936 @default.
• W3109850965 hasAuthorship W3109850965A5008384446 @default.
• W3109850965 hasAuthorship W3109850965A5012081749 @default.
• W3109850965 hasAuthorship W3109850965A5016536735 @default.
• W3109850965 hasAuthorship W3109850965A5017143127 @default.
• W3109850965 hasAuthorship W3109850965A5018132469 @default.
• W3109850965 hasAuthorship W3109850965A5025637560 @default.
• W3109850965 hasAuthorship W3109850965A5026435595 @default.
• W3109850965 hasAuthorship W3109850965A5034797711 @default.
• W3109850965 hasAuthorship W3109850965A5045333833 @default.
• W3109850965 hasAuthorship W3109850965A5045484635 @default.
• W3109850965 hasAuthorship W3109850965A5047377148 @default.
• W3109850965 hasAuthorship W3109850965A5048381438 @default.
• W3109850965 hasAuthorship W3109850965A5055501716 @default.
• W3109850965 hasAuthorship W3109850965A5064457355 @default.
• W3109850965 hasAuthorship W3109850965A5064789713 @default.
• W3109850965 hasAuthorship W3109850965A5075361314 @default.
• W3109850965 hasAuthorship W3109850965A5080853611 @default.
• W3109850965 hasAuthorship W3109850965A5084314819 @default.
• W3109850965 hasAuthorship W3109850965A5088414167 @default.
• W3109850965 hasAuthorship W3109850965A5089682169 @default.
• W3109850965 hasAuthorship W3109850965A5090816037 @default.
• W3109850965 hasBestOaLocation W31098509651 @default.
• W3109850965 hasConcept C126322002 @default.
• W3109850965 hasConcept C142724271 @default.
• W3109850965 hasConcept C16005928 @default.
• W3109850965 hasConcept C197934379 @default.
• W3109850965 hasConcept C204787440 @default.
• W3109850965 hasConcept C27081682 @default.
• W3109850965 hasConcept C2776260265 @default.
• W3109850965 hasConcept C2777402515 @default.
• W3109850965 hasConcept C2777575956 @default.
• W3109850965 hasConcept C2779650986 @default.
• W3109850965 hasConcept C2780564577 @default.
• W3109850965 hasConcept C31760486 @default.
• W3109850965 hasConcept C535046627 @default.

• next